Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price gapped down prior to trading on Tuesday following insider selling activity. The stock had previously closed at $31.01, but opened at $28.59. Hims & Hers Health shares last traded at $30.4870, with a volume of 18,685,922 shares trading hands.

Specifically, CFO Oluyemi Okupe sold 36,922 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the transaction, the chief financial officer owned 281,867 shares in the company, valued at $7,300,355.30. This trade represents a 11.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 18,005 shares of the stock in a transaction on Friday, April 17th. The shares were sold at an average price of $27.83, for a total transaction of $501,079.15. Following the transaction, the chief financial officer owned 270,046 shares of the company’s stock, valued at $7,515,380.18. This trade represents a 6.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Morgan Stanley lowered their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and increased their price objective for the company from $13.25 to $24.00 in a research report on Tuesday, March 10th. Barclays increased their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Needham & Company LLC upgraded shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $31.86.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Investor optimism around HIMS’s peptide pipeline and a reported collaboration with Novo Nordisk drove a sizable rally (the stock rallied sharply in recent sessions as traders positioned ahead of earnings). HIMS Stock Rockets Nearly 50% Following FDA Peptide News and Novo Partnership
• Neutral Sentiment: Company strategy progress: HIMS is building a data‑driven, personalized care platform (adding labs and multi‑cancer testing) that could expand addressable services over time, a positive long‑term thesis though not an immediate earnings catalyst. Hims & Hers Builds Scalable Data-Driven Personalized Care Platform
• Neutral Sentiment: Near‑term event risk: HIMS has an upcoming May 11 earnings report and recent Q1 results showed an EPS beat with revenue roughly in line — investors are positioning ahead of that print, which can fuel volatility either way. MarketBeat HIMS Coverage
• Negative Sentiment: Competitive threat: Amazon unveiled a GLP‑1 weight‑loss program today — a direct competitive move into a key growth category for HIMS (weight‑loss/GLP‑1 related services), which pressured the stock as investors reassess TAM and pricing power. Stock Market Today, April 21: Hims and Hers Health Drops as Amazon Unveils Competing Weight Loss Program
• Negative Sentiment: Insider selling: CFO Oluyemi Okupe sold multiple blocks of shares (executed under a Rule 10b5‑1 plan). While 10b5‑1 plans mute the signal, the disclosed sales have added short‑term selling pressure and negative sentiment. SEC Form 4 – Insider Sale

Hims & Hers Health Trading Down 3.9%

The firm has a market cap of $6.79 billion, a PE ratio of 58.43, a P/E/G ratio of 2.95 and a beta of 2.32. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The company’s 50 day moving average price is $20.20 and its two-hundred day moving average price is $31.76.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the firm posted $0.11 earnings per share. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.61 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HIMS. Farallon Capital Management LLC grew its holdings in shares of Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. Norges Bank bought a new position in shares of Hims & Hers Health in the fourth quarter worth about $62,153,000. Invesco Ltd. grew its holdings in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the last quarter. Clear Street Group Inc. bought a new position in shares of Hims & Hers Health in the third quarter worth about $87,372,000. Finally, Marex Group plc grew its holdings in shares of Hims & Hers Health by 162.2% in the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after purchasing an additional 1,496,707 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.